2 research outputs found
Discovering a Racemate Polycyclic Prenylated Acylphloroglucinol with Unprecedented Skeleton by an ESI-LCMS Analytical Approach
By an ESI-LC/MS analytical method,
a racemate 1 consisting
of a pair of unprecedented phloroglucinol enantiomers with a 5/6/5/5/6
fused ring system, (−)-garcinielliptone HG [((−)-1a] and (+)-garcinielliptone HH [(+)-1b], was
obtained from the isolates of a CH2Cl2 extract
of Garcinia subelliptica (heartwood). The gross structure
of 1 was elucidated by spectroscopic methods and X-ray
single-crystal diffraction data. The absolute configurations of 1a and 1b were unequivocally assigned by analysis
on the calculated and experimental circular dichroism spectra and
X-ray single-crystal diffraction data
Glucose Transporter 1‑Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy
Tumour hypoxia plays an important role in modulating
tumorigenesis,
angiogenesis, invasion, immunosuppression, resistance to treatment,
and even maintenance of the stemness of cancer stem cells (CSCs).
Moreover, the targeting and treatment of hypoxic cancer cells and
CSCs to reduce the influence of tumor hypoxia on cancer therapy remains
an imperative clinical problem that needs to be addressed. Since cancer
cells upregulate the expression of glucose transporter 1 (GLUT1) through
the Warburg effect, we considered the possibility of GLUT1-mediated
transcytosis in cancer cells and developed a tumor hypoxia-targeting
nanomedicine. Our experimental results indicate that glucosamine-labeled
liposomal ceramide can be efficiently transported between cancer cells
by GLUT1 transporters and substantially accumulated in the hypoxic
area in in vitro CSC spheroids and in vivo tumor xenografts. We also verified the effects of exogenous ceramide
on tumor hypoxia, including important bioactivities such as upregulation
of p53 and retinoblastoma protein (RB), downregulation of hypoxia-inducible
factor-1 alpha (HIF-1α) expression, disruption of the OCT4-SOX2
network of stemness, and inhibition of CD47 and PD-L1 expression.
To achieve an ideal therapeutic outcome, we combined treatment of
glucosamine-labeled liposomal ceramide with paclitaxel and carboplatin,
and we found an excellent synergistic effect, with tumor clearance
being noted in three-fourths of the mice. Overall, our findings provide
a potential therapeutic strategy for the treatment of cancer
